Drugs for relapse prevention of alcoholism: ten years of progress

Trends in Pharmacological Sciences

Volumn 29, Issue 3, 2008, Pages 109-115

  Spanagel, Rainer ^a   Kiefer, Falk ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 8 (2,3,3A,4,5,6 HEXAHYDRO 1H PHENALEN 1 YL) 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DECAN 4 ONE; ACAMPROSATE; AMPA RECEPTOR ANTAGONIST; ANTALARMIN; BROMOCRIPTINE; BUPRENORPHINE; CARFENTANIL; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPENTIXOL; GLUTAMATE RECEPTOR AGONIST; HYDRAZIDE BENOZOIC ACID; LISURIDE; LY 404039; MEMANTINE; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; NALMEFENE; NALOXONEBENZOYLHYDRAZONE; NALTREXONE; NERAMEXANE; NOCICEPTIN RECEPTOR ANTAGONIST; NORBINALTORPHIMINE; OPIATE ANTAGONIST; PLACEBO; RIMONABANT; TIAPRIDE; TOPIRAMATE; UNCLASSIFIED DRUG;

ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DRUG SAFETY; GENE TARGETING; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; RECURRENT DISEASE; RISK ASSESSMENT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SOCIOECONOMICS; SPECTROSCOPY; STRESS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UPREGULATION;

EID: 39749088094     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.12.005     Document Type: Article

References (65)

1. World Health Organization (2004) Global Status Report on Alcohol 2004 , World Health Organization ( http://www.who.int/substance_abuse/publications/global_status_report_2004_overview.pdf )}
2. Y. Shaham The reinstatement model of drug relapse: history, methodology and major findings Psychopharmacology (Berl.) 168 2003 3 20
3. S.N. Katner Reinstatement of alcohol-seeking behavior by drug-associated discriminative stimuli after prolonged extinction in the rat Neuropsychopharmacology 20 1999 471 479
4. D. Bachteler The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behaviour Neuropsychopharmacology 30 2005 1104 1111
5. C. Sanchis-Segura R. Spanagel Behavioral assessment of drug-reinforcement and addictive features in rodents: an overview Addict. Biol. 11 2006 2 38
6. R. Spanagel W. Zieglgänsberger Anti-craving compounds: new pharmacological tools to study addictive processes Trends Pharmacol. Sci. 18 1997 54 59
7. R.L. Bell The alcohol-preferring P rat and animal models of excessive alcohol drinking Addict. Biol. 11 2006 270 288
8. J.C. Crabbe Alcohol-related genes: contributions from studies with genetically engineered mice Addict. Biol. 11 2006 195 269
9. T. Zghoul Ethanol self-administration and reinstatement of ethanol-seeking behavior in Per1(Brdm1) mutant mice Psychopharmacology (Berl.) 190 2007 13 19
10. R.T. Khisti Characterization of the ethanol-deprivation effect in substrains of C57BL/6 mice Alcohol 40 2006 119 126
11. M. Srisurapanont N. Jarusuraisin Opioid antagonists for alcohol dependence Cochrane Database Syst. Rev. 2005 10.1002/14651858.CD001867.pub2
12. P.M. Monti Naltrexone's effect on cue-elicited craving among alcoholics in treatment Alcohol. Clin. Exp. Res. 23 1999 1386 1394
13. J.E. Grant Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling Am. J. Psychiatry 163 2006 303 312
14. F. Kiefer Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone Addict. Biol. 13 2008 124 129
15. A.D. Lê Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress Neuropsychopharmacology 21 1999 435 444
16. B.M. Walker G.F. Koob Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence Neuropsychopharmacology 33 2008 643 652
17. S.M. Hölter Kappa-opioid receptors and relapse-like drinking in long-term ethanol experienced rats Psychopharmacology (Berl.) 153 2000 93 102
18. M. Heilig G.F. Koob A key role for corticotropin-releasing factor in alcohol dependence Trends Neurosci. 30 2007 399 406
19. R. Ciccocioppo Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats Psychopharmacology (Berl.) 172 2004 170 178
20. R. Martin-Fardon Nociceptin prevents stress-induced ethanol- but not cocaine-seeking behavior in rats Neuroreport 11 2000 1939 1943
21. R. Ciccocioppo Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system Biol. Psychiatry 61 2007 4 12
22. J. Kakko 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial Lancet 361 2003 662 668
23. A. Kuzmin The nociceptin/orphanin FQ receptor agonist Ro 64-6198 reduces alcohol self-administration and prevents relapse-like alcohol drinking Neuropsychopharmacology 32 2007 902 910
24. J. Huang Association between the nociceptin receptor gene (OPRL1) single nucleotide polymorphisms and alcohol dependence Addict. Biol. 13 2008 88 94
25. K. Mann The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis Alcohol. Clin. Exp. Res. 28 2004 51 63
26. R.F. Anton Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial J. Am. Med. Assoc. 295 2006 2003 2017
27. F. Kiefer K. Mann Pharmacotherapy and behavioral intervention for alcohol dependence J. Am. Med. Assoc. 296 2006 1727 1728
28. R. Spanagel The circadian clock gene Period2 alters the glutamatergic system and thereby modulates alcohol consumption Nat. Med. 11 2005 35 42
29. J.T. Gass M.F. Olive Glutamatergic substrates of drug addiction and alcoholism Biochem. Pharmacol. 75 2007 218 265
30. V. Vengeliene The role of the NMDA receptor complex in alcohol relapse: A pharmacological mapping study using the alcohol deprivation effect Neuropharmacology 48 2005 822 829
31. E.M. Krupitsky Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients Am. J. Psychiatry 164 2007 519 523
32. J.E. Chatterton Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits Nature 415 2002 793 798
33. H.T. Mueller J.H. Meador-Woodruff NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder Schizophr. Res. 71 2004 361 370
34. C. Sanchis-Segura Involvement of AMPA receptor GluR-C subunit in alcohol-seeking and relapse J. Neurosci. 26 2006 1231 1238
35. B.A. Johnson Oral topiramate for treatment of alcohol dependence: a randomised controlled trial Lancet 361 2003 1677 1685
36. B.A. Johnson Topiramate for treating alcohol dependence: a randomized controlled trial J. Am. Med. Assoc. 298 2007 1641 1651
37. P. Backström MPEP reduces ethanol-seeking and relapse behavior Neuropsychopharmacology 29 2004 921 928
38. J.P. Schroeder The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats Psychopharmacology (Berl.) 179 2005 262 270
39. M.S. Cowen The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system Addict. Biol. 10 2005 233 242
40. Y. Zhao Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala J. Neurosci. 26 2006 9967 9974
41. S.T. Patil Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial Nat. Med. 13 2007 1102 1107
42. R. Spanagel F. Weiss The dopamine hypothesis of reward: past and current status Trends Neurosci. 22 1999 521 527
43. X. Liu F. Weiss Reversal of ethanol-seeking behavior by D1 and D2 antagonists in an animal model of relapse: differences in antagonist potency in previously ethanol-dependent versus nondependent rats J. Pharmacol. Exp. Ther. 300 2002 882 889
44. V. Vengeliene The D3 receptor plays an essential role in alcohol craving and relapse but not in alcohol reinforcement processes FASEB J. 20 2006 2223 2233
45. C.A. Heidbreder Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behaviour in mice Addict. Biol. 12 2007 35 50
46. C.A. Heidbreder The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence Brain Res. Brain Res. Rev. 49 2005 77 105
47. D. Blomeyer Interaction between CRHR1 gene and stressful life events predicts adolescent heavy alcohol use Biol. Psychiatry 63 2008 146 151
48. A.C. Hansson Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress Proc. Natl. Acad. Sci. U. S. A. 103 2006 15236 15241
49. F. Kiefer Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anti-craving treatment? Biol. Psychiatry 60 2006 74 76
50. I. Racz A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking J. Neurosci. 23 2003 2453 2458
51. D. Economidou Effect of the cannabinoid CB1 receptor antagonist SR141716A on ethanol self-administration and ethanol-seeking behaviour in rats Psychopharmacology (Berl.) 183 2006 394 403
52. G.L. Gessa Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats Alcohol Alcohol. 40 2005 46 53
53. K. Cahill M. Ussher Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation Cochrane Database Syst. Rev. 18 2007 CD005353
54. C.S. Barr Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques Arch. Gen. Psychiatry 64 2007 369 376
55. D.W. Oslin A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients Neuropsychopharmacology 28 2003 1546 1552
56. Anton, R. et al. Variation in the mu-opiate receptor gene (OPRM1) predicts response to naltrexone: results from the combine study. Arch. Gen. Psychiatry (in press)
57. S.M. Chan Protein microarrays for multiplex analysis of signal transduction pathways Nat. Med. 10 2004 1390 1396
58. A. Heinz Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil Arch. Gen. Psychiatry 62 2005 57 64
59. A. Meyer-Lindenberg D.R. Weinberger Intermediate phenotypes and genetic mechanisms of psychiatric disorders Nat. Rev. Neurosci. 7 2006 818 827
60. A.C. Ahn The clinical applications of a systems approach PLoS Med. 3 2007 e209
61. F. Kiefer Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study Arch. Gen. Psychiatry 60 2003 92 99
62. G.F. Feeney Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centre's experience with pharmacotherapy Alcohol Alcohol. 41 2006 321 327
63. Karpyak, V.M. et al. Alcoholism treatment with naltrexone and acamprosate: what can influence the outcome. Addiction (in press)
64. R. Spanagel K. Mann Drugs for Relapse Prevention of Alcoholism 2005 Birkhäuser
65. J.M. Littleton Challenges to medications development in treating alcohol dependence: an international perspective Alcohol Alcohol. 39 2004 271 275